Is Checkpoint Therapeutics, Inc. (CKPT) a Buy, Sell, or Hold?
Checkpoint Therapeutics, Inc.
NASDAQ:CKPT
$4.26 USD
$0 (0.0%)
- Volume
- 8.63M
- Average Volume
- 3.08M
- Market Capitalization
- $367.72M
- P/E Ratio
- -3.00
- Dividend Yield
- 0.00%
- Price Target
- $4.10
- Year High
- $4.50
- Year Low
- $1.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.37
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | James F. Oliviero III, |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CKPT |
| CUSIP | 162828206 |
| CIK | 0001651407 |
| Web | https://www.checkpointtx.com |
| Phone | 781 652 4500 |
| Currency | USD |
| Employees | 24 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.37 |
| Quick Ratio | 0.37 |
| Cash Ratio | 0.33 |
Sales & Book Value
| Annual Sales | $41000 |
| Price / Sales | 8968.86 |
| Cash Flow | -0.78 |
| Price / Cash Flow | -11.82 |
| Price / Book | -13.39 |
Price Target and Rating
| Average Stock Price Forecast | $4.10 |
| High Stock Price Forecast | $4.10 |
| Low Stock Price Forecast | $4.10 |
| Forecast Upside/Downside | 3.90% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.42 |
| Trailing P/E Ratio | -3.00 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-56.24M |
| Net Margin | -137170.73% |
| Pretax Margin | -137170.73% |
| Return on Equity | 438.14% |
| Return on Assets | -752.78% |
Financials Score
| AltmanZ Score | -9.25 |
| Piotroski Score | 3.00 |
| Working Capital | 16.3M |
| Total Assets | 34.16M |
| Ebit | -67.6M |
| Market Cap | 367.72M |
| Total Liabilities | 17.87M |
Poll Results
About Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock
Checkpoint Therapeutics, Inc. is a clinical-stage company specializing in immunotherapy and targeted oncology. Its mission involves discovering, advancing, and bringing to market innovative therapeutic solutions for individuals battling solid tumor cancers. The company's pipeline features several key candidates, including Cosibelimab, a leading fully-human IgG1 monoclonal antibody. This therapy is designed to directly bind to programmed death ligand-1 (PD-L1), thereby inhibiting its interaction with programmed death receptor-1 and B7.1 receptors. Another significant antibody in development is CK-302, a human agonistic antibody intended to bind and activate signaling within GITR-expressing cells. Beyond antibodies, Checkpoint Therapeutics is advancing Olafertinib, a third-generation epiderm ... al growth factor receptor (EGFR) inhibitor specifically for patients with EGFR mutation-positive non-small cell lung cancer. Its portfolio also includes CK-103, a highly selective and potent small molecule designed to inhibit bromodomain and extra-terminal (BET) bromodomains. Furthermore, a fully human, preclinical anti-carbonic anhydrase IX (CAIX) antibody is being developed, which aims to identify and destroy CAIX-expressing cells through both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). To broaden its reach, Checkpoint Therapeutics has established collaboration agreements with TG Therapeutics, Inc. These partnerships focus on the joint development and commercialization of specific assets related to its licenses in the area of hematological malignancies. Established in 2014, Checkpoint Therapeutics is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Fortress Biotech, Inc.
Frequently Asked Questions
-
What is the current Checkpoint Therapeutics, Inc. (CKPT) stock price?
-
Checkpoint Therapeutics, Inc.(NASDAQ:CKPT) stock price is $4.26 in the last trading session. During the trading session, CKPT stock reached the peak price of $4.5 while $1.8 was the lowest point it dropped to. The percentage change in CKPT stock occurred in the recent session was 0.0% while the dollar amount for the price change in CKPT stock was $0.
-
CKPT's industry and sector of operation?
-
The NASDAQ listed CKPT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CKPT?
-
William Garrett Gray | Chief Financial Officer, Corporate Secretary & Treasurer
James F. Oliviero | President, Chief Executive Officer & Director
|
|
| -
How many employees does CKPT have?
-
Number of CKPT employees currently stands at 24. CKPT operates from 95 Sawyer Road, Waltham, MA 02453, US.
-
Link for CKPT official website?
-
Official Website of CKPT is: https://www.checkpointtx.com
-
How do I contact CKPT?
-
CKPT could be contacted at phone #781 652 4500 and can also be accessed through its website. CKPT operates from 95 Sawyer Road, Waltham, MA 02453, US.
-
How many shares of CKPT are traded daily?
-
The average number of CKPT shares traded daily for last 3 months was 3.08M.
-
What is the market cap of CKPT currently?
-
The market value of CKPT currently stands at $367.72M with its latest stock price at $4.26